Abstract: The present invention relates to supported catalysts which are composed of titanium oxide hydrates coated with nanoscale gold particles. The catalysts of the present invention have increased activity over known catalysts.

Abstract: Lactone compounds of formula (1) are useful as monomers to form base resins for use in chemically amplified resist compositions adapted for micropatterning lithography. R1 is H or C1-6 alkyl, R2 is H or an acyl or alkoxycarbonyl group of 1-15 carbon atoms which may be substituted with halogen atoms, Z is a divalent C1-15 organic group which forms a lactone ring with the carbonyloxy group, k is 0 or 1, and m is an integer from 0 to 5.

Abstract: A process for producing cyclopropanecarbonitrile involves reacting cyclopropanecarbaldoxime with acetic anhydride to obtain a mixture containing acetic acid and cyclopropanecarbonitrile. The acetic acid can be removed from the mixture through azeotropic distillation of acetic acid with a solvent that forms with acetic acid an azeotropic mixture having an azeotropic point lower than the boiling point of the cyclopropanecarbonitrile.

Abstract: A process for the preparation of taxane derivatives by reacting 10-deacetylbaccatin III protected at the 7-and 1-positions with trichloroacetyl groups with a compound of formula and subsequent removal of the protective groups and hydrolysis of the oxazolidine ring.

Abstract: Compounds of formula (I) or pesticidally acceptable salts thereof, compositions containing them and methods of use.

Abstract: Compounds of formula (I) in which R1 is halo-C1-10 alkyl; halo-C2-10 alkenyl; or (CH2)nY in which n is 1 or 2 and Y is OH, CN, N3, OR3, SH, S(O)pR4, S(O)3H, NH2, NHR5, NR6R7, NHCOR8, NO2, CO2H, CONHR9, 1H-tetrazol-5-yl, 5-phenyltetrazol-2-yl or PO3H2; R3, R5, R6, R7, R8 and R9 are each selected independently from C1-4 alkyl, aryl and aryl-C1-4 alkyl; R4 is selected from C1-4 alkyl, aryl, aryl-C1-4 alkyl, and 1H-tetrazol-5-yl, carboxy-(1-4C)alkyl and 1H-tetrazol-5-yl-C1-4 alkyl; and p is 0, 1, 2 or 3; or a salt or ester thereof, provided that R1 is not methoxymethyl, modulate metabotropic glutamate receptor function and are useful in treating disorders of the central nervous system.

Abstract: Novel compounds having the Formulas 1 through 8, wherein the symbols have the meaning defined in the specification, and certain previously known compounds have been discovered to act as inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids. The compound can also be used in co-treatment with retinoids.

Abstract: The present invention relates to phosphoric acid derivatives represented by general formula (I), wherein each symbol is as defined in the description and nontoxic salts thereof. Because of having a TNF&agr; production inhibitory effect, the compounds represented by general formula (I) are useful as preventives and/or remedies for rheumatoid arthritis, ulcerative colitis, Crohn's disease, hepatitis, sepsis, hemorrhagic shock, multiple sclerosis, cerebral infarction, diabetes, interstitial pneumonia, uveitis, pain, glomerulonephritis, HIV-associated diseases, cachexia, myocardial infarction, chronic heart failure, oral aphtha, Hansen's disease, infection, etc.

Abstract: A process for the production of gamma-butyrolactone. Starting from maleic and/or succinic anhydride the conversion takes place in the vapor phase of a Cu/Cr catalyst.

Abstract: The invention relates to novel 2-(2-chlorophenyl)-3,4-dihydro-2H-pyrrole derivatives of the formula (I) in which Ar represents substituted phenyl, to a plurality of processes for their preparation and to their use as pesticides.

Abstract: A multi-step method of synthesizing ketorolac, an analgesic compound, is shown. Several of the reactions and intermediate compounds are novel. The reaction sequence begins with the known compound N-2-bromoethylpyrrole.

Abstract: A method for producing an &agr;-aminonitrile, is disclosed, which method includes the step of oxidizing a tertiary amine with oxygen by using a transition metal catalyst in the presence of a cyanide. The &agr;-aminonitrile thus obtained can be easily converted to amino acids as well as various nitrogen-containing physiologically active materials.

Abstract: A 4-oxatricyclo[4.3.1.13,8]undecan-5-one derivative is shown by the following formula (1): wherein R is a hydrogen atom or a (meth)acryloyl group, and carbon atoms constituting a ring may have a substituent in addition to the substituents indicated in the formula. This compound is a novel 4-oxatricyclo[4.3.1.13,8]undecan-5-one derivative having a hydroxyl group or a (meth)acryloyloxy group at the 1-position.

Abstract: The present invention relates to novel herbicidal phenoxypropionic acid N-alkyl-N-2-fluorophenyl amides represented in formula (1), a method for preparing thereof, their use to control barnyard grass produced from rice and composition as suitable herbicides. In said formula, R is methyl or ethyl group; X is hydrogen, halogen, cyano, C1˜C6 alkyl, C1˜C6 alkoxy, C1˜C3 haloalkyl substituted with 1 to 3 of halogen atom(s), C1˜C3 haloalkoxy substituted with 1 to 3 of halogen atom(s), C2˜C4 alkoxyalkoxy, phenoxy, benzyloxy, C2˜C6 alkenyl, C2˜C6 alkinyl, C2˜C6 alkkenyloxy, C2˜C6 alkinyloxy, or phenyl group; Y is hydrogen or fluoro; n is an integer of 1 or 2 and when n is 2, X can be in a combination of other substituents.

Abstract: The present invention provides medicines for treating cardiac insufficiency which contain as an active ingredient indane derivatives of formula (I) wherein R1 represents hydrogen atom, nitro group, cyano group, C1-6 alkylcarbonylamino, R2 and R3 each independently represent C1-6 alkyl group, R4 represents hydroxyl group or C1-6 alkylcarbonyloxy group or represents a bond or oxygen atom together with R5, R5 represents hydrogen atom or represents a bond or oxygen atom together with R4, R6 represents hydrogen atom, hydroxyl group or NR7R8, n means 0 or an integer of 1 to 4, X represents C═O, CH2, SO2 or NR16, Y represents NR17 when X is C═O, CH2 or SO2 and represents C═O when X is NR16, Z is absent when Y represents NR17 or represents NR18 when Y is C═O, W represents aromatic groups or lactam rings, or pharmaceutically acceptable salt thereof.

Abstract: The present invention provides a process, which includes: preparing 3-alkoxyacrylonitrile from 3,3-dialkoxypropionitrile by catalytically eliminating alcohol from 3,3-dialkoxypropionitrile in the presence of at least one aromatic sulfonic acid catalyst and at least one high-boiling solvent. Another embodiment of the invention provides a method of producing a pharmaceutical compound, which includes the above-described process. Another embodiment of the invention provides a method of producing a cosmetic product, which includes the above-described process.

Abstract: The present invention is concerned with a novel process for the preparation of a hydroxybenzothiophene that is an intermediate for synthesizing pharmaceutically active substances, e.g. 5-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-7-benzothiophenylmethyl]-2,4-thiazolidinedione and the corresponding sodium salt which are useful in the treatment of diabetes.

Abstract: Novel pyrroles, pyrazoles and triazoles, pharmaceutical compositions containing these compounds and their use as endothelin receptor antagonists are described.

Abstract: A process for the formation of a di(hydroxyalkylaryl) aryl phosphate is disclosed which comprises the reaction of an o-alkyl substituted aromatic diol, e.g., an o-alkyl substituted hydroquinone such as o-t-butylhydro-quinone, and monoaryl dihalophosphate, such as monophenyl dichlorophosphate. This process can, in particular, be used to make certain di(hydroxy-o-alkylphenyl) phenyl phosphate compounds, preferably those that are p-hydroxy, such as di(p-hydroxy-o-t-butylphenyl) phenyl phosphate.

Abstract: Novel cyclic ether vitamin D3 compounds having a cyclic ether side chain are disclosed. These compounds were first identified as metabolites of 3-epi vitamin D3 produced via a tissue-specific metabolic pathway which catalyzes the formation of a cyclic ether structure. Also disclosed are 1&agr;(OH) 3-epi vitamin D3 compounds, which are produced via the epimerization of a 3-&bgr;-hydroxyl group of 1&agr;(OH) vitamin D3 precursor in vivo. The vitamin D3 compounds of the present invention can be used as substitutes for natural and synthetic vitamin D3 compounds.